U.S., Oct. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07881458) titled 'A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes' on Oct. 12.
Brief Summary: The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes.
Participation in the study will last about 2 years.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Obesity
Overweight
Diabetes Mellitus, Type 2
Intervention:
DRUG: eloralintide and tirzepatide
Administered SC
DRUG: Tirzepatide
Administered SC
Recruitmen...